Vertex Pharmaceuticals Incorporated (0QZU.L)
USD 490.18
(-2.47%)
USD 490.18
(-2.47%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 3.61 Billion USD | 8.96% |
| 2022 | 3.32 Billion USD | 41.84% |
| 2021 | 2.34 Billion USD | -13.63% |
| 2020 | 2.71 Billion USD | 130.43% |
| 2019 | 1.17 Billion USD | -43.88% |
| 2018 | 2.09 Billion USD | 695.83% |
| 2017 | 263.48 Million USD | 335.14% |
| 2016 | -112.05 Million USD | 79.92% |
| 2015 | -558.11 Million USD | 24.43% |
| 2014 | -738.55 Million USD | -65.96% |
| 2013 | -445.02 Million USD | -315.79% |
| 2012 | -107.03 Million USD | -461.91% |
| 2011 | 29.57 Million USD | 103.92% |
| 2010 | -754.62 Million USD | -17.62% |
| 2009 | -641.57 Million USD | -39.52% |
| 2008 | -459.85 Million USD | -17.53% |
| 2007 | -391.27 Million USD | -89.12% |
| 2006 | -206.89 Million USD | -1.71% |
| 2005 | -203.41 Million USD | -22.36% |
| 2004 | -166.24 Million USD | 15.51% |
| 2003 | -196.76 Million USD | -81.15% |
| 2002 | -108.62 Million USD | -64.0% |
| 2001 | -66.23 Million USD | -67.01% |
| 2000 | -39.65 Million USD | 3.27% |
| 1999 | -41 Million USD | -23.87% |
| 1998 | -33.1 Million USD | -67.17% |
| 1997 | -19.8 Million USD | 50.5% |
| 1996 | -40 Million USD | -86.05% |
| 1995 | -21.5 Million USD | -22.16% |
| 1994 | -17.6 Million USD | -980.0% |
| 1993 | 2 Million USD | 123.53% |
| 1992 | -8.5 Million USD | -66.67% |
| 1991 | -5.1 Million USD | -18.6% |
| 1990 | -4.3 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | 1.04 Billion USD | 129.09% |
| 2024 Q2 | -3.59 Billion USD | -426.81% |
| 2024 Q1 | 1.09 Billion USD | 13.5% |
| 2023 Q1 | 699.8 Million USD | -14.54% |
| 2023 Q4 | 968.8 Million USD | -6.42% |
| 2023 FY | 3.61 Billion USD | 8.96% |
| 2023 Q2 | 915.7 Million USD | 30.85% |
| 2023 Q3 | 1.03 Billion USD | 13.06% |
| 2022 Q4 | 818.9 Million USD | -11.99% |
| 2022 Q1 | 762.1 Million USD | -1.04% |
| 2022 Q2 | 810.5 Million USD | 6.35% |
| 2022 FY | 3.32 Billion USD | 41.84% |
| 2022 Q3 | 930.5 Million USD | 14.81% |
| 2021 Q1 | 653.13 Million USD | 8.1% |
| 2021 Q2 | 66.92 Million USD | -89.75% |
| 2021 Q4 | 770.1 Million USD | -9.61% |
| 2021 FY | 2.34 Billion USD | -13.63% |
| 2021 Q3 | 851.92 Million USD | 1172.98% |
| 2020 Q1 | 602.75 Million USD | 3.35% |
| 2020 FY | 2.71 Billion USD | 130.43% |
| 2020 Q4 | 604.19 Million USD | -9.48% |
| 2020 Q3 | 667.43 Million USD | -20.28% |
| 2020 Q2 | 837.27 Million USD | 38.91% |
| 2019 FY | 1.17 Billion USD | -43.88% |
| 2019 Q1 | 268.63 Million USD | -82.67% |
| 2019 Q4 | 583.23 Million USD | 914.0% |
| 2019 Q3 | 57.51 Million USD | -78.49% |
| 2019 Q2 | 267.42 Million USD | -0.45% |
| 2018 Q2 | 207.36 Million USD | -1.38% |
| 2018 Q4 | 1.55 Billion USD | 1104.33% |
| 2018 FY | 2.09 Billion USD | 695.83% |
| 2018 Q1 | 210.26 Million USD | 108.83% |
| 2018 Q3 | 128.74 Million USD | -37.91% |
| 2017 Q3 | -102.95 Million USD | -672.08% |
| 2017 Q2 | 17.99 Million USD | -92.74% |
| 2017 Q1 | 247.75 Million USD | 652.03% |
| 2017 Q4 | 100.68 Million USD | 197.8% |
| 2017 FY | 263.48 Million USD | 335.14% |
| 2016 Q2 | -64.52 Million USD | -54.99% |
| 2016 FY | -112.05 Million USD | 79.92% |
| 2016 Q1 | -41.63 Million USD | 44.87% |
| 2016 Q3 | -41.84 Million USD | 35.16% |
| 2016 Q4 | 32.94 Million USD | 178.74% |
| 2015 Q4 | -75.51 Million USD | 20.64% |
| 2015 Q1 | -198.6 Million USD | -12.43% |
| 2015 Q2 | -188.84 Million USD | 4.91% |
| 2015 FY | -558.11 Million USD | 24.43% |
| 2015 Q3 | -95.14 Million USD | 49.62% |
| 2014 Q3 | -170.06 Million USD | -6.7% |
| 2014 Q2 | -159.38 Million USD | 31.44% |
| 2014 Q4 | -176.65 Million USD | -3.88% |
| 2014 FY | -738.55 Million USD | -65.96% |
| 2014 Q1 | -232.45 Million USD | -624.91% |
| 2013 Q3 | -124.12 Million USD | -117.13% |
| 2013 Q2 | -57.16 Million USD | 81.44% |
| 2013 Q1 | -308.01 Million USD | -304.5% |
| 2013 Q4 | 44.28 Million USD | 135.68% |
| 2013 FY | -445.02 Million USD | -315.79% |
| 2012 Q4 | -76.14 Million USD | -32.33% |
| 2012 Q3 | -57.54 Million USD | 11.38% |
| 2012 Q2 | -64.93 Million USD | -170.89% |
| 2012 Q1 | 91.59 Million USD | -42.26% |
| 2012 FY | -107.03 Million USD | -461.91% |
| 2011 FY | 29.57 Million USD | 103.92% |
| 2011 Q1 | -176.09 Million USD | 2.38% |
| 2011 Q2 | -174.06 Million USD | 1.15% |
| 2011 Q3 | 221.11 Million USD | 227.02% |
| 2011 Q4 | 158.62 Million USD | -28.26% |
| 2010 Q4 | -180.39 Million USD | 13.67% |
| 2010 FY | -754.62 Million USD | -17.62% |
| 2010 Q1 | -165.27 Million USD | -4.18% |
| 2010 Q2 | -200 Million USD | -21.02% |
| 2010 Q3 | -208.95 Million USD | -4.48% |
| 2009 Q1 | -162.67 Million USD | -14.29% |
| 2009 Q4 | -158.64 Million USD | -6.07% |
| 2009 FY | -641.57 Million USD | -39.52% |
| 2009 Q2 | -171.29 Million USD | -5.3% |
| 2009 Q3 | -149.56 Million USD | 12.69% |
| 2008 FY | -459.85 Million USD | -17.53% |
| 2008 Q1 | -96.15 Million USD | -12.13% |
| 2008 Q3 | -130.04 Million USD | -42.4% |
| 2008 Q2 | -91.32 Million USD | 5.03% |
| 2008 Q4 | -142.33 Million USD | -9.45% |
| 2007 Q2 | -117.76 Million USD | -45.88% |
| 2007 Q1 | -80.72 Million USD | -195.23% |
| 2007 FY | -391.27 Million USD | -89.12% |
| 2007 Q3 | -107.03 Million USD | 9.11% |
| 2007 Q4 | -85.75 Million USD | 19.88% |
| 2006 FY | -206.89 Million USD | -1.71% |
| 2006 Q4 | -27.34 Million USD | 47.21% |
| 2006 Q3 | -51.8 Million USD | 33.29% |
| 2006 Q2 | -77.65 Million USD | -55.05% |
| 2006 Q1 | -50.08 Million USD | -31.36% |
| 2005 Q4 | -38.13 Million USD | 52.08% |
| 2005 Q2 | -40.98 Million USD | 8.35% |
| 2005 Q3 | -79.57 Million USD | -94.15% |
| 2005 FY | -203.41 Million USD | -22.36% |
| 2005 Q1 | -44.72 Million USD | -4.56% |
| 2004 Q3 | -38.77 Million USD | 12.42% |
| 2004 Q2 | -44.26 Million USD | -9.47% |
| 2004 Q1 | -40.43 Million USD | 1.44% |
| 2004 FY | -166.24 Million USD | 15.51% |
| 2004 Q4 | -42.76 Million USD | -10.31% |
| 2003 Q2 | -45.79 Million USD | -322.2% |
| 2003 Q4 | -41.02 Million USD | 52.52% |
| 2003 Q3 | -86.42 Million USD | -88.7% |
| 2003 Q1 | 20.61 Million USD | 164.24% |
| 2003 FY | -196.76 Million USD | -81.15% |
| 2002 Q1 | -22.06 Million USD | -576.9% |
| 2002 FY | -108.62 Million USD | -64.0% |
| 2002 Q3 | -33.45 Million USD | -59.15% |
| 2002 Q4 | -32.08 Million USD | 4.09% |
| 2002 Q2 | -21.01 Million USD | 4.75% |
| 2001 Q2 | -12.1 Million USD | -36.49% |
| 2001 Q3 | -46.97 Million USD | -288.02% |
| 2001 Q1 | -8.87 Million USD | 21.18% |
| 2001 Q4 | -3.26 Million USD | 93.06% |
| 2001 FY | -66.23 Million USD | -67.01% |
| 2000 Q2 | 12.61 Million USD | 178.06% |
| 2000 FY | -39.65 Million USD | 3.27% |
| 2000 Q4 | -11.25 Million USD | 54.73% |
| 2000 Q3 | -24.85 Million USD | -297.08% |
| 2000 Q1 | -16.15 Million USD | -1050.53% |
| 1999 Q2 | -10.8 Million USD | 38.64% |
| 1999 Q1 | -17.6 Million USD | -39.68% |
| 1999 FY | -41 Million USD | -23.87% |
| 1999 Q3 | -14.3 Million USD | -32.41% |
| 1999 Q4 | 1.7 Million USD | 111.89% |
| 1998 Q4 | -12.6 Million USD | -447.83% |
| 1998 FY | -33.1 Million USD | -67.17% |
| 1998 Q1 | -8.4 Million USD | -23.53% |
| 1998 Q2 | -9.8 Million USD | -16.67% |
| 1998 Q3 | -2.3 Million USD | 76.53% |
| 1997 Q1 | -5.8 Million USD | -48.72% |
| 1997 Q2 | -1.4 Million USD | 75.86% |
| 1997 Q4 | -6.8 Million USD | -15.25% |
| 1997 Q3 | -5.9 Million USD | -321.43% |
| 1997 FY | -19.8 Million USD | 50.5% |
| 1996 Q2 | -22.3 Million USD | -197.33% |
| 1996 Q4 | -3.9 Million USD | 38.1% |
| 1996 FY | -40 Million USD | -86.05% |
| 1996 Q3 | -6.3 Million USD | 71.75% |
| 1996 Q1 | -7.5 Million USD | -837.5% |
| 1995 Q1 | -4.7 Million USD | 4.08% |
| 1995 FY | -21.5 Million USD | -22.16% |
| 1995 Q3 | -6.9 Million USD | 23.33% |
| 1995 Q4 | -800 Thousand USD | 88.41% |
| 1995 Q2 | -9 Million USD | -91.49% |
| 1994 FY | -17.6 Million USD | -980.0% |
| 1994 Q1 | -3.2 Million USD | -136.78% |
| 1994 Q2 | -5.5 Million USD | -71.88% |
| 1994 Q4 | -4.9 Million USD | -25.64% |
| 1994 Q3 | -3.9 Million USD | 29.09% |
| 1993 FY | 2 Million USD | 123.53% |
| 1993 Q1 | -3.3 Million USD | -22.22% |
| 1993 Q2 | -800 Thousand USD | 75.76% |
| 1993 Q4 | 8.7 Million USD | 422.22% |
| 1993 Q3 | -2.7 Million USD | -237.5% |
| 1992 Q2 | -1.9 Million USD | -18.75% |
| 1992 Q1 | -1.6 Million USD | -23.08% |
| 1992 FY | -8.5 Million USD | -66.67% |
| 1992 Q3 | -2.2 Million USD | -15.79% |
| 1992 Q4 | -2.7 Million USD | -22.73% |
| 1991 Q1 | - USD | 0.0% |
| 1991 Q4 | -1.3 Million USD | -8.33% |
| 1991 FY | -5.1 Million USD | -18.6% |
| 1991 Q3 | -1.2 Million USD | 14.29% |
| 1991 Q2 | -1.4 Million USD | 0.0% |
| 1990 Q1 | - USD | 0.0% |
| 1990 Q2 | - USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 Q3 | - USD | 0.0% |
| 1990 FY | -4.3 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | -2059.086% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 4190.822% |
| Myriad Genetics, Inc. | -112 Million USD | 3331.786% |
| Evolus, Inc. | -61.68 Million USD | 5967.877% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 1088.19% |
| Agilent Technologies, Inc. | 1.24 Billion USD | -191.903% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 1128.038% |
| uniQure N.V. | -308.47 Million USD | 1273.374% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 7719.408% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 1410.851% |
| bluebird bio, Inc. | -211.91 Million USD | 1808.059% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 6779.708% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 922.184% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | -3310.213% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 2487.851% |
| Dynavax Technologies Corporation | -6.38 Million USD | 56753.623% |
| Editas Medicine, Inc. | -153.21 Million USD | 2462.37% |
| FibroGen, Inc. | -284.23 Million USD | 1373.467% |
| Geron Corporation | -184.12 Million USD | 2065.817% |
| Blueprint Medicines Corporation | -506.98 Million USD | 813.948% |
| IQVIA Holdings Inc. | 1.35 Billion USD | -166.539% |
| Illumina, Inc. | -1.16 Billion USD | 411.766% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 915.157% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | 8677.454% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | -1349.579% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 3154.18% |
| Adicet Bio, Inc. | -142.65 Million USD | 2637.257% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 775.327% |
| Insmed Incorporated | -749.56 Million USD | 582.892% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 852.215% |
| Mettler-Toledo International Inc. | 788.77 Million USD | -358.887% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 9180.783% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | -274945.593% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 141.913% |
| Waters Corporation | 642.23 Million USD | -463.595% |
| Zoetis Inc. | 2.34 Billion USD | -54.42% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 39.623% |
| Biogen Inc. | 1.16 Billion USD | -211.739% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 1503.865% |
| Nektar Therapeutics | -276.05 Million USD | 1411.183% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 4313.982% |
| Perrigo Company plc | -12.7 Million USD | 28600.787% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 1612.97% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 3373.908% |
| Verastem, Inc. | -87.36 Million USD | 4242.983% |
| Imunon, Inc. | -19.51 Million USD | 18647.806% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 8215.092% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 1829.813% |
| Homology Medicines, Inc. | -53.74 Million USD | 6835.017% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 8.448% |
| OPKO Health, Inc. | -188.86 Million USD | 2016.521% |
| Exelixis, Inc. | 207.76 Million USD | -1642.161% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | -1185.397% |
| TG Therapeutics, Inc. | 12.67 Million USD | -28463.763% |
| Incyte Corporation | 597.59 Million USD | -505.69% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 575.95% |